NCT06097065

Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 2,860 (estimated)
• Sponsor: Zhujiang Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

Through the MALDI-TOF MS platform, explore the proteomics and peptidomics differences of fasting serum/plasma and urine between non pregnant people with normal glucose tolerance test and prediabetes /diabetes patients, pregnant people with normal glucose tolerance test and pregnant diabetes patients respectively; To explore the role of its proteomics and peptidomics differences in the diagnosis of prediabetes and diabetes, and to establish a new method of differential diagnosis by using the omics data and key characteristic peaks to find potential new diagnostic markers.

Detailed description

Prediabetes is a stage of abnormal glucose metabolism between normal blood glucose level and diabetes, which is a "gray zone" between normal and abnormal, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both. It is a very important high-risk group of diabetes. Diabetes is a group of metabolic diseases characterized by hyperglycemia caused by a variety of causes. Gestational diabetes mellitus refers to varying degrees of abnormal glucose metabolism that occur during pregnancy. This project aims to detect differential feature peaks through MALDI-TOF MS technology between non pregnant people with normal glucose tolerance test and prediabetes/diabetes patients, pregnant people with normal glucose tolerance test and pregnant diabetes patients respectively and to establish a clinical predictive diagnostic model based on differences, and to evaluate the model.

Conditions

• Prediabetes
• Diabetes Mellitus
• Gestational Diabetes Mellitus
• Proteomics

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Oral Glucose Tolerance Test	Grouping based on detected oral glucose tolerance test results without any other intervention.

Timeline

• Start date: 2022-05-20
• Primary completion: 2025-12-31
• Completion: 2026-12-31
• First posted: 2023-10-24
• Last updated: 2023-10-24

Locations

1 site across 1 country: China